Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co-morbidities

被引：15
作者：
De, D. [1 ]
Kaushik, A. [1 ]
Handa, S. [1 ]
Mahajan, R. [1 ]
Schmidt, E. [2 ,3 ]
机构：
[1] Postgrad Inst Med Educ & Res, Dept Dermatol Venereol & Leprol, Chandigarh, India
[2] Univ Lubeck, Dept Dermatol, Lubeck, Germany
[3] Univ Lubeck, Lubeck Inst Expt Dermatol LIED, Lubeck, Germany
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2021年 / 35卷 / 07期
关键词：
IGE;
D O I：
10.1111/jdv.17229
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E469 / E472
页数：4
相关论文
共 10 条
  • [1] Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature
    Balakirski, G.
    Alkhateeb, A.
    Merk, H. F.
    Leverkus, M.
    Megahed, M.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (10) : 1778 - 1782
  • [2] Pathogenicity of IgE in autoimmunity: Successful treatment of bullous pemphigoid with omalizumab
    Fairley, Janet A.
    Baum, Christian L.
    Brandt, Debra S.
    Messingham, Kelly A. N.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (03) : 704 - 705
  • [3] IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants
    Freire, P. C.
    Munoz, C. H.
    Stingl, G.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (06) : 1644 - 1653
  • [4] Basement membrane zone IgE deposition is associated with bullous pemphigoid disease severity and treatment results
    Kamata, A.
    Kurihara, Y.
    Funakoshi, T.
    Takahashi, H.
    Kuroda, K.
    Hachiya, T.
    Amagai, M.
    Yamagami, J.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (05) : 1221 - 1227
  • [5] Eosinophils Mediate Tissue Injury in the Autoimmune Skin Disease Bullous Pemphigoid
    Lin, Lan
    Hwang, Bin-Jin
    Culton, Donna A.
    Li, Ning
    Burette, Susan
    Koller, Beverly H.
    Messingham, Kelly A.
    Fairley, Janet A.
    Lee, James J.
    Hall, Russell P.
    An, Lijia
    Diaz, Luis A.
    Liu, Zhi
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : 1032 - 1043
  • [6] Lonowski Sarah, 2020, JAAD Case Rep, V6, P228, DOI 10.1016/j.jdcr.2020.01.002
  • [7] S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update
    Schmidt, Enno
    Sticherling, Michael
    Sardy, Miklos
    Eming, Ruediger
    Goebeler, Matthias
    Hertl, Michael
    Hofmann, Silke C.
    Hunzelmann, Nicolas
    Kern, Johannes S.
    Kramer, Harald
    Nast, Alexander
    Orzechowski, Hans-Dieter
    Pfeiffer, Christiane
    Schuster, Volker
    Sitaru, Cassian
    Zidane, Miriam
    Zillikens, Detlef
    Worm, Margitta
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 (05): : 516 - 526
  • [8] Pemphigoid diseases
    Schmidt, Enno
    Zillikens, Detlef
    [J]. LANCET, 2013, 381 (9863) : 320 - 332
  • [9] Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity
    van Beek, Nina
    Luettmann, Nadine
    Huebner, Franziska
    Recke, Andreas
    Karl, Ingolf
    Schulze, Franziska Sophie
    Zillikens, Detlef
    Schmidt, Enno
    [J]. JAMA DERMATOLOGY, 2017, 153 (01) : 30 - 38
  • [10] Omalizumab therapy for bullous pemphigoid
    Yu, Kenneth K.
    Crew, Ashley B.
    Messingham, Kelly A. N.
    Fairley, Janet A.
    Woodley, David T.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 71 (03) : 468 - 474
1